Pricing Log in Create free account
Saturday 17 October 2026 Export STLN’s income statement to Excel — free account

Starling Oncology, Inc.

STLN Healthcare Medical Care Facilities

Starling Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.7 million, up 27.8% from fiscal 2024. In the quarter to June 2026, revenue grew 34.6%, EPS grew 46.7%, free cash flow grew 196.7% and total debt rose 6.46%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

6.43 0.48 −6.95%
Market cap
$690.9M
P/E
0.0×
Fwd P/E
−32.5×
Dividend yield
—
F-score
4/9
Altman Z
1.42
Beneish M
−3.39
Dividend safety
n/a
Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 2.69
Total sells 2.81
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — 5 1 2 2 2 1 — —
Sell 1 1 1 — — 1 — 1 1 1 — —
Insider Ownership 32.02%

Capital & Financial Ratios $m

Market Cap 690.88
Revenue 587.24
Net Income (36.29)
Free Cash Flow (3.29)
Net Debt 38.77
Current Ratio 1.36
Debt/Equity (3.21) (negative: negative equity)
P/E ratio 0.00
Fwd P/E (32.50) (negative: loss-making)
P/S ratio 1.13
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 69.91% (at or above 15%: strong)
Next Y EPS Growth 100.00% (at or above 15%: strong)
Next Y revenue growth 32.28% (at or above 10%: strong)
Next 5Y EPS Growth 51.70% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.2×, against a ten-year median of 0.6×; over the ten years it ranged from 0.1× in 2024 to 2.8× in 2022.
P/S against its own 10 years 80.55%
10-year low 10-year high
EV/Sales against its own 10 years 81.13%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2020 Powerpack
2019 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 83 50 34 41
Receivables 43 49 59 67
Inventory 14 10 17 20
Other — — — —
143 112 113 129
2023 2024 2025 Q'26
Payables 14 24 43 60
ST’ Debt — — — —
Other — — — —
35 52 71 95

Compound Annual Growth %

10y 5y 3y
Sales — 21.80% 25.81%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 147 161 — — —
’25 104 120 137 142 503
’24 95 99 100 100 393
’23 76 80 82 86 324
’22 55 61 65 71 252
’21 49 50 52 52 203
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) 12 — — —
’25 (5) (10) (13) 3 (25)
’24 (16) (16) 1 4 (27)
’23 (15) (9) (8) (4) (36)
’22 (17) (10) (20) (14) (62)
’21 0 (7) (3) (23) (33)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) 11 — — —
’25 (5) (11) (13) 2 (28)
’24 (16) (17) 1 2 (30)
’23 (17) (10) (9) (5) (41)
’22 (18) (12) (22) (16) (67)
’21 0 (8) (4) (24) (36)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.02) (0.08) — — —
’25 (0.21) (0.15) (0.14) (0.06) (0.54)
’24 (0.22) (0.17) (0.18) (0.14) (0.71)
’23 (0.33) (0.19) (0.19) (0.21) (0.92)
’22 0.21 (0.06) (0.03) (0.15) 0.00
’21 (0.02) 0.05 (0.05) (0.15) (0.16)
’20 (0.15) (0.46) (0.42) 0.78 (0.24)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — 9.70 5.52 0.86 0.33 0.13 0.25

Analyst estimates 2026–2028

Powerpack
High — — — — 11.00 12.66 10.74 2.66 2.50 4.88
People
People Employees — — — 3 3 658 750 800 825 641
Revenue/emp, $m — — — 0.00 62.51 0.31 0.34 0.41 0.48 0.78
Income, $m
Income, $m Revenue — — — — 188 203 252 324 393 503
Gross margin, % — — — — 19.67 20.12 20.63 18.37 13.73 15.20
EBT — — — 0 (15) (12) 0 (83) (65) (61)
EBT margin, % — — — 0.00 (7.90) (5.71) (0.04) (25.63) (16.44) (12.08)
Net income — 0 — 0 (14) (11) 0 (83) (65) (61)
Depreciation — — — — 3 3 16 26 12 15
Per share, $
Per share, $ Revenue — — — 0.00 3.17 3.07 3.47 4.40 5.24 5.44
Earnings — — — 0.00 (0.24) (0.16) 0.00 (0.92) (0.71) (0.54)
Cash flow — — — 0.00 0.01 (0.49) (0.85) (0.49) (0.35) (0.27)
Capex — — — 0.00 (0.02) (0.05) (0.08) (0.06) (0.05) (0.03)
Free cash flow — — — 0.00 (0.01) (0.54) (0.92) (0.55) (0.40) (0.30)
Book value — — — 0.00 0.48 1.57 1.69 0.77 0.05 (0.17)
Shares, m — — — 5 59 66 73 74 75 92
Valuation, ×
Valuation, × P/E — — — — 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — — — 0.00 3.18 0.46 0.52 0.06 0.65
P/B — — — — 22.72 6.20 0.95 2.97 6.48 0.00
EV/Sales — — — — 0.00 2.65 0.49 0.54 0.17 0.74
EV/FCF — — — — 1,268.51 (15.12) (1.85) (4.25) (2.21) (13.42)
Cash, $m
Cash, $m Operating cash flow — — — — 1 (33) (62) (36) (27) (25)
Capex — — — — (1) (3) (6) (5) (4) (3)
Free cash flow — — — — (1) (36) (67) (41) (30) (28)
Balance, $m
Balance, $m Working capital — — — 0 1 124 101 109 60 42
Total debt — — — — 12 0 81 87 93 77
Net debt — — — 0 6 (115) 7 4 43 44
Shareholders’ equity — — — 0 28 104 123 57 4 (16)
Returns, %
Returns, % ROA — — — (9.20) (43.57) (8.12) 0.07 (35.28) (33.86) (35.93)
ROIC — — — 0.00 (15.05) 0.00 (39.40) (78.92) (79.86) (80.21)
ROE — — — (0.02) (101.85) (16.52) 0.13 (92.20) (213.36) 999.19
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Starling Oncology, Inc. vs peers in Medical Care Facilities (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
HCSG Healthcare Services Group, Inc. $1.5B 12.2× 19.2× +2.69% (above 0%: growing) n/m −26.02% (below 0%: shrinking) 15.89% 4.72% Compare
NUTX Nutex Health Inc. $1.4B 7.1× 6.3× −13.62% (below 0%: shrinking) n/m +19.44% (above 0%: growing) 67.04% 57.75% Compare
USPH U.S. Physical Therapy, Inc. $1.3B 504× 27.7× +8.47% (above 0%: growing) −56.90% (below 0%: shrinking) −8.24% (below 0%: shrinking) 19.59% 10.25% Compare
INNV InnovAge Holding Corp. $1.2B — (loss-making) 17.2× +18.31% (above 0%: growing) n/m +85.44% (above 0%: growing) 23.88% 3.87% Compare
STLN Starling Oncology, Inc. $690.9M — (loss-making) — (loss-making) +34.62% (above 0%: growing) n/m +196.69% (above 0%: growing) 16.84% (2.86%)
MCTA Charming Medical Limited $497.3M — — — — — — — Compare
CYH Community Health Systems, Inc. $421.6M 1.5× — (loss-making) −9.83% (below 0%: shrinking) −75.83% (below 0%: shrinking) +500.00% (above 0%: growing) 85.81% 13.77% Compare
AUNA Auna S.A. $392.3M 76.0× 5.2× +20.51% (above 0%: growing) −61.29% (below 0%: shrinking) +121.08% (above 0%: growing) 35.72% 13.09% Compare
SRTA Strata Critical Medical, Inc. $384.0M 9.0× — (loss-making) +60.74% (above 0%: growing) n/m +150.33% (above 0%: growing) 20.98% (7.46%) Compare
Median of peers $863.6M 10.6× 17.2× +8.47% −61.29% +85.44% 23.88% 10.25%

All 55 Medical Care Facilities stocks →

Starling Oncology, Inc. (STLN) key facts

  • Strength: Starling Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.7 million, up 27.8% from fiscal 2024.
  • Starling Oncology, Inc. (STLN) is a Medical Care Facilities company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, STLN traded at $6.43, a market capitalization of $690.9 million.
  • Return on equity was 999.2% and debt-to-equity -3.21.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 1.42 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Starling Oncology, Inc. (STLN) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/STLN · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com